Clarence Peter

Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA.

JSB-Partners LP offers specialized investment banking and advisory services to biotechnology and pharmaceutical companies. Its services include product partnerships, mergers and acquisitions, private placements and public underwritings. The company was founded by Wolfgang Rudolph Ralph Stoiber in 1999 and is headquartered in Boston, MA.

Vero Biotech LLC is a biotechnology company, which focuses on the design, development and commercialization of inhaled nitric oxide delivery systems to address the unmet medical needs of patients with cardiopulmonary conditions. It develops a drug, GeNOsyl to meet the needs of patients and care providers. The company was founded by David H. Fine in 2006 and is headquartered in Atlanta, GA.

Metriopharm AG engages in the development and manufacture of pharmaceutical products. It offers pipeline, indicators and clinical trials. The company was founded by Ekkehard Brysch and Wolfgang Brysch in 2007 and is headquartered in Zurich, Switzerland.

MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts.

Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland.

Inotrem SA specializes in the development of therapeutic approaches based on its proprietary TREM-1 platform. The firm focuses on the control of immune reactions in acute inflammatory diseases. The company was founded by Jean-Jacques Garaud, Marc Derive and Sebastien Gibot in 2013 and is headquartered in Paris, France.

Atalanta Therapeutics, Inc. develops RNA interference based therapeutics to treat neurodegenerative diseases. The company is based in Boston, MA. The company was founded by Neil Aronin, Craig C. Mello, Anastasia Khvorova, Jim Glasheen. The CEO is Alicia Secor.